Hussain A - Search Results

1

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME. McKay RR, et al. Among authors: hussain a. Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22. Cancer. 2015. PMID: 25903013 Free PMC article. Clinical Trial.

2

Management of advanced/metastatic prostate cancer: 2000 update.

Hussain A, Dawson N. Hussain A, et al. Oncology (Williston Park). 2000 Dec;14(12):1677-88; discussion 1688, 1691-4. Oncology (Williston Park). 2000. PMID: 11204373 Free article. Review.

3

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. Savarese DM, et al. Among authors: hussain a. J Clin Oncol. 2001 May 1;19(9):2509-16. doi: 10.1200/JCO.2001.19.9.2509. J Clin Oncol. 2001. PMID: 11331330 Clinical Trial.

4

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Hussain A, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):22-31. doi: 10.1016/s0093-7754(01)90151-4. Semin Oncol. 2001. PMID: 11685725 Clinical Trial.

5

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.

Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A. Dawson NA, et al. Among authors: hussain a. Clin Cancer Res. 2004 Dec 1;10(23):7812-9. doi: 10.1158/1078-0432.CCR-04-0310. Clin Cancer Res. 2004. PMID: 15585612 Clinical Trial.

6

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, Guo C. Hussain A, et al. J Clin Oncol. 2005 Apr 20;23(12):2789-96. doi: 10.1200/JCO.2005.07.152. J Clin Oncol. 2005. PMID: 15837994 Clinical Trial.

7

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Tang Y, et al. Among authors: hussain a. Clin Cancer Res. 2006 Jan 1;12(1):169-74. doi: 10.1158/1078-0432.CCR-05-1388. Clin Cancer Res. 2006. PMID: 16397039

8

What constitutes high-risk locally advanced prostate cancer?

Mannuel HD, Hussain A. Mannuel HD, et al. Among authors: hussain a. Clin Genitourin Cancer. 2005 Dec;4(3):193-6. doi: 10.3816/CGC.2005.n.032. Clin Genitourin Cancer. 2005. PMID: 16425988 Review.

9

Thapsigargin resistance in human prostate cancer cells.

O'Neill JP, Velalar CN, Lee DI, Zhang B, Nakanishi T, Tang Y, Selaru F, Ross D, Meltzer SJ, Hussain A. O'Neill JP, et al. Among authors: hussain a. Cancer. 2006 Aug 1;107(3):649-59. doi: 10.1002/cncr.22027. Cancer. 2006. PMID: 16770788 Free article.

10

Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer.

Mannuel HD, Hussain A. Mannuel HD, et al. Among authors: hussain a. Clin Genitourin Cancer. 2006 Jun;5(1):43-9. doi: 10.3816/CGC.2006.n.016. Clin Genitourin Cancer. 2006. PMID: 16859578 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,640 results

Search Page

Filters